PMID- 35792840
OWN - NLM
STAT- MEDLINE
DCOM- 20220708
LR  - 20220811
IS  - 1267-8694 (Print)
IS  - 1267-8694 (Linking)
VI  - 26
IP  - 3
DP  - 2022 May 1
TI  - [Atypical New Lav Blot I (HIV-1 Western blot) profile with loss of antibodies to 
      gp120, gp41 and polymerase in a HIV-1 subtype A infected patient at AIDS stage].
PG  - 253-255
LID - 10.1684/vir.2022.0935 [doi]
FAU - Guiraud, Vincent
AU  - Guiraud V
FAU - Talb, Yasmina
AU  - Talb Y
FAU - Ramahefasolo, Charline
AU  - Ramahefasolo C
FAU - Stefic, Karl
AU  - Stefic K
FAU - Gautheret-Dejean, Agnès
AU  - Gautheret-Dejean A
LA  - fre
PT  - Journal Article
TT  - Profil atypique de western blot VIH-1 (New Lav Blot I) avec perte d’anticorps 
      anti-gp120, anti-gp41 et anti-polymérase au cours d’une infection par du VIH-1 
      sous-type A au stade sida.
PL  - France
TA  - Virologie (Montrouge)
JT  - Virologie (Montrouge, France)
JID - 9802575
RN  - 0 (Antibodies)
RN  - 0 (HIV Envelope Protein gp120)
RN  - EC 2.7.7.- (Nucleotidyltransferases)
SB  - IM
MH  - *Acquired Immunodeficiency Syndrome
MH  - Antibodies
MH  - Blotting, Western
MH  - HIV Envelope Protein gp120
MH  - *HIV-1
MH  - Humans
MH  - Nucleotidyltransferases
EDAT- 2022/07/07 06:00
MHDA- 2022/07/09 06:00
CRDT- 2022/07/06 10:35
PHST- 2022/07/06 10:35 [entrez]
PHST- 2022/07/07 06:00 [pubmed]
PHST- 2022/07/09 06:00 [medline]
AID - 10.1684/vir.2022.0935 [doi]
PST - ppublish
SO  - Virologie (Montrouge). 2022 May 1;26(3):253-255. doi: 10.1684/vir.2022.0935.

PMID- 37458587
OWN - NLM
STAT- MEDLINE
DCOM- 20230825
LR  - 20240118
IS  - 1098-660X (Electronic)
IS  - 0095-1137 (Print)
IS  - 0095-1137 (Linking)
VI  - 61
IP  - 8
DP  - 2023 Aug 23
TI  - Are Confirmatory Assays Reliable for HIV-1/HIV-2 Infection Differentiation? A 
      Multicenter Study.
PG  - e0061923
LID - 10.1128/jcm.00619-23 [doi]
LID - e00619-23
AB  - Immunoblots remain the gold standard for HIV-1/HIV-2 infection confirmation. 
      However, their ability to differentiate HIV-1 from HIV-2 infection on an 
      antigenically diversified HIV-1 and HIV-2 panel remain uncommon. We performed a 
      multicenter study on 116 serum samples accounting for most of the diversity of 
      HIV-1 (9 different subtypes in group M, 17 circulating recombinant forms (CRFs), 
      and 3 group O) and HIV-2 (groups A and B), evaluating seven confirmatory assays 
      (six commercially available assays and one in-house assay) with genotyping as the 
      reference. The assays were INNO-LIA HIV I/II score, HIV-2 blot 1.2, HIV blot 2.2, 
      New Lav blot I and II, Geenius, and an in-house serotyping enzyme-linked 
      immunosorbent assay (ELISA). Among the HIV-1 samples, INNO-LIA, HIV blot 2.2, New 
      Lav blot I, Geenius, and serotyping had comparable high sensitivities, from 98% 
      to 100%, whereas HIV-2 blot 1.2 and New Lav blot II had high rates of 
      "undetermined" results (85% and 95%, respectively). HIV-2 blot 1.2 and New Lav 
      blot II misclassified 7% and 5% of HIV-1 samples as HIV-2, respectively, and 
      HIV-2 blot 1.2 had an 8% false-negative rate. Among the HIV-2 samples, INNO-LIA, 
      New Lav blot II, HIV-2 blot 1.2, and serotyping had high sensitivities, from 96% 
      to 100%. HIV blot 2.2 misclassified 17% of HIV-2 samples as HIV-1/HIV-2 dual 
      infections. New Lav blot I misclassified 19% of HIV-2 samples as HIV-1 with a 
      high (81%) undetermined rate, and Geenius misclassified 2% as HIV-1 and 7% as 
      untypeable HIV positive. For HIV-1/HIV-2 dual infection, the results were less 
      sensitive, with at most 87.5% for INNO-LIA and Geenius and 75% for HIV blot 2.2 
      and serotyping. Overall, confirmatory assays remain useful for most cases, with 
      the exception of HIV-1/HIV-2 dual-infection suspicion.
FAU - Guiraud, Vincent
AU  - Guiraud V
AUID- ORCID: 0000-0002-4301-3771
AD  - AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière-Charles Foix, Service de 
      Virologie, Paris, France.
AD  - Sorbonne Université, INSERM U1136, Institut Pierre Louis d'Epidémiologie et de 
      Santé Publique (IPLESP), Paris, France.
FAU - Bocobza, Jonathan
AU  - Bocobza J
AD  - AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière-Charles Foix, Service de 
      Virologie, Paris, France.
FAU - Desmonet, Marion
AU  - Desmonet M
AD  - AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière-Charles Foix, Service de 
      Virologie, Paris, France.
FAU - Damond, Florence
AU  - Damond F
AD  - AP-HP, University Hospital Bichat-Claude Bernard, Service de Virologie, Paris, 
      France.
AD  - Université Paris Cité, IAME, INSERM, Paris, France.
FAU - Plantier, Jean-Christophe
AU  - Plantier JC
AD  - Université de Rouen Normandie, Inserm UMR1311 DYNAMICURE, et CHU de Rouen, 
      Laboratoire de Virologie associé au CNR du VIH, Rouen, France.
FAU - Moreau, Ghislaine
AU  - Moreau G
AD  - AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière-Charles Foix, Service de 
      Virologie, Paris, France.
FAU - Wirden, Marc
AU  - Wirden M
AD  - AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière-Charles Foix, Service de 
      Virologie, Paris, France.
AD  - Sorbonne Université, INSERM U1136, Institut Pierre Louis d'Epidémiologie et de 
      Santé Publique (IPLESP), Paris, France.
FAU - Stefic, Karl
AU  - Stefic K
AUID- ORCID: 0000-0002-9686-9194
AD  - Université de Tours, UMR Inserm 1259, and CHU de Tours, Laboratoire associé au 
      CNR du VIH, Tours, France.
FAU - Barin, Francis
AU  - Barin F
AUID- ORCID: 0000-0003-4148-6900
AD  - Université de Tours, UMR Inserm 1259, and CHU de Tours, Laboratoire associé au 
      CNR du VIH, Tours, France.
FAU - Gautheret-Dejean, Agnès
AU  - Gautheret-Dejean A
AUID- ORCID: 0000-0003-0048-0318
AD  - AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière-Charles Foix, Service de 
      Virologie, Paris, France.
AD  - Université Paris Cité, INSERM UMR-S 1139, 3PHM, Paris, France.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20230717
PL  - United States
TA  - J Clin Microbiol
JT  - Journal of clinical microbiology
JID - 7505564
RN  - 0 (HIV Antibodies)
SB  - IM
MH  - Humans
MH  - HIV-2/genetics
MH  - *HIV-1
MH  - Sensitivity and Specificity
MH  - *HIV Infections/diagnosis
MH  - *HIV Seropositivity
MH  - HIV Antibodies
PMC - PMC10446874
OTO - NOTNLM
OT  - Geenius
OT  - HIV confirmation
OT  - HIV-1
OT  - HIV-2
OT  - INNO-LIA
OT  - Western blot
OT  - differentiation
COIS- The authors declare no conflict of interest.
EDAT- 2023/07/17 15:08
MHDA- 2023/08/25 06:42
PMCR- 2024/01/17
CRDT- 2023/07/17 10:05
PHST- 2023/08/25 06:42 [medline]
PHST- 2023/07/17 15:08 [pubmed]
PHST- 2023/07/17 10:05 [entrez]
PHST- 2024/01/17 00:00 [pmc-release]
AID - 00619-23 [pii]
AID - jcm.00619-23 [pii]
AID - 10.1128/jcm.00619-23 [doi]
PST - ppublish
SO  - J Clin Microbiol. 2023 Aug 23;61(8):e0061923. doi: 10.1128/jcm.00619-23. Epub 
      2023 Jul 17.

PMID- 27789052
OWN - NLM
STAT- MEDLINE
DCOM- 20170407
LR  - 20170407
IS  - 0151-9638 (Print)
IS  - 0151-9638 (Linking)
VI  - 143
IP  - 11
DP  - 2016 Nov
TI  - [Primary HIV infection].
PG  - 749-751
LID - S0151-9638(16)30414-8 [pii]
LID - 10.1016/j.annder.2016.09.029 [doi]
FAU - Timsit, F-J
AU  - Timsit FJ
AD  - Centre clinique et biologique des MST, hôpital Saint-Louis, 42, rue Bichat, 75010 
      Paris, France. Electronic address: centre.mst@aphp.fr.
FAU - Janier, M
AU  - Janier M
AD  - Centre clinique et biologique des MST, hôpital Saint-Louis, 42, rue Bichat, 75010 
      Paris, France.
FAU - Vernay-Vaïsse, C
AU  - Vernay-Vaïsse C
AD  - CIDAG/CIDDIST MDS Aubagne, 10, allée Antide-Boyer, 13400 Aubagne, France.
FAU - Bouscarat, F
AU  - Bouscarat F
AD  - Dermatologie, hôpital Bichat-Claude-Bernard, 46, rue Henri-Huchard, 75018 Paris, 
      France.
FAU - Fouéré, S
AU  - Fouéré S
AD  - Centre clinique et biologique des MST, hôpital Saint-Louis, 42, rue Bichat, 75010 
      Paris, France.
FAU - Dupin, N
AU  - Dupin N
AD  - Service de dermatologie, hôpital Cochin, 27, rue du Faubourg-Saint-Jacques, 75014 
      Paris, France.
CN  - Section MST de la SFD
LA  - fre
PT  - Journal Article
PT  - Practice Guideline
TT  - Primo-infection VIH.
DEP - 20161024
PL  - France
TA  - Ann Dermatol Venereol
JT  - Annales de dermatologie et de venereologie
JID - 7702013
RN  - 0 (Anti-Retroviral Agents)
RN  - 0 (Biomarkers)
RN  - 0 (DNA, Viral)
SB  - IM
MH  - Anti-Retroviral Agents/therapeutic use
MH  - Biomarkers/blood
MH  - Blotting, Western
MH  - CD4-CD8 Ratio
MH  - DNA, Viral/genetics
MH  - Diagnosis, Differential
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Genotype
MH  - HIV Infections/*diagnosis/drug therapy/epidemiology
MH  - Humans
MH  - Polymerase Chain Reaction
EDAT- 2016/10/30 06:00
MHDA- 2017/04/08 06:00
CRDT- 2016/11/07 06:00
PHST- 2016/10/30 06:00 [pubmed]
PHST- 2017/04/08 06:00 [medline]
PHST- 2016/11/07 06:00 [entrez]
AID - S0151-9638(16)30414-8 [pii]
AID - 10.1016/j.annder.2016.09.029 [doi]
PST - ppublish
SO  - Ann Dermatol Venereol. 2016 Nov;143(11):749-751. doi: 
      10.1016/j.annder.2016.09.029. Epub 2016 Oct 24.

PMID- 22334109
OWN - NLM
STAT- MEDLINE
DCOM- 20120613
LR  - 20220330
IS  - 1527-3172 (Electronic)
IS  - 1527-3172 (Linking)
VI  - 14
IP  - 1
DP  - 2012 Jan
TI  - HIV‑2 antibody detection after indeterminate or negative HIV‑1 Western blot in 
      Cuba, 2005-2008.
PG  - 25-9
LID - 10.37757/MR2012V14.N1.6 [doi]
AB  - INTRODUCTION Differentiating between HIV-1 and HIV-2 infection is the first step 
      to understanding HIV transmission, epidemiology and pathogenesis in geographical 
      areas where both viruses circulate. In Cuba, positive results in mixed HIV-1/2 
      screening assays are confirmed by HIV-1 Western blot. Indeterminate results 
      constitute the main limitation of this test and HIV-2 infection is among their 
      possible causes; hence the importance of second-stage screening and confirmatory 
      tests for HIV-2 infection. OBJECTIVE Investigate the contribution of HIV-2 
      antibodies to negative or indeterminate HIV-1 Western blot results in serum 
      samples from 2005 through 2008 in Cuba. METHODS HIV-2 reactivity was studied 
      using the ELISA DAVIH-VIH-2 diagnostic kit (Cuba) in 1723 serum samples with 
      negative or indeterminate results for HIV-1 Western blot from January 2005 
      through December 2008. Duplicate sera reactive by ELISA were confirmed by HIV-2 
      Western blot, results interpreted according to WHO criteria. The epidemiological 
      interview established by Cuba's National Program for Prevention and Control 
      Sexually-Transmitted Diseases and HIV/AIDS was applied to HIV-2 Western 
      blot-positive patients. RESULTS Among all sera studied, HIV-2 ELISA identified 12 
      reactive serum samples (0.70%) and 1711 non-reactive (99.30%). Western blot 
      analysis of the 12 ELISA-reactive samples confirmed two positive samples 
      (16.67%), 4 negative (33.33%) and 6 indeterminate (50%). Positive samples reacted 
      against the p16, p26, gp36, p53, p56, p68 and gp105 proteins. All 12 
      ELISA-reactive samples belonged to the HIV-1 Western blot indeterminate group. 
      The two HIV-2-positive samples showed well defined reactivity to gp160, p53, p55 
      and p34 of HIV-1. HIV-1 seroconversion was observed in all 10 remaining samples 
      during serological followup. CONCLUSIONS Two new HIV-2 seropositive cases were 
      diagnosed using DAVIH-VIH-2 and HIV-2 Western blot in indeterminate HIV-1 Western 
      blot samples. Results support the recommendation that HIV-2 Western blot be 
      included in the diagnostic algorithm for HIV-1/2 to followup negative or 
      indeterminate HIV-1 Western blot results. KEYWORDS Diagnosis, laboratory 
      techniques and procedures, antibodies, HIV-2, Western blot, enzyme-linked 
      immunosorbent assay, algorithm, Cuba.
FAU - Díaz, Dervel F
AU  - Díaz DF
AD  - AIDS Research Laboratory (LISIDA), Havana, Cuba. feloany@infomed.sld.cu
FAU - Ortiz, Eva
AU  - Ortiz E
FAU - Martín, Dayamí
AU  - Martín D
FAU - Nibot, Carmen
AU  - Nibot C
FAU - Rizo, Adis
AU  - Rizo A
FAU - Silva, Eladio
AU  - Silva E
LA  - eng
PT  - Journal Article
PL  - United States
TA  - MEDICC Rev
JT  - MEDICC review
JID - 100964771
SB  - IM
MH  - Adult
MH  - *Blotting, Western/methods
MH  - Cuba/epidemiology
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Female
MH  - HIV Infections/*diagnosis/epidemiology/virology
MH  - HIV Seronegativity
MH  - HIV Seropositivity/diagnosis/epidemiology/virology
MH  - *HIV-1
MH  - *HIV-2
MH  - Humans
MH  - Prospective Studies
MH  - Young Adult
EDAT- 2012/02/16 06:00
MHDA- 2012/06/14 06:00
CRDT- 2012/02/16 06:00
PHST- 2012/02/16 06:00 [entrez]
PHST- 2012/02/16 06:00 [pubmed]
PHST- 2012/06/14 06:00 [medline]
AID - 10.37757/MR2012V14.N1.6 [doi]
PST - ppublish
SO  - MEDICC Rev. 2012 Jan;14(1):25-9. doi: 10.37757/MR2012V14.N1.6.

PMID- 33485940
OWN - NLM
STAT- MEDLINE
DCOM- 20211027
LR  - 20211027
IS  - 1879-0984 (Electronic)
IS  - 0166-0934 (Linking)
VI  - 290
DP  - 2021 Apr
TI  - Immunoblots may not be effective in confirming the recency of HIV-1 infection.
PG  - 114074
LID - S0166-0934(21)00013-6 [pii]
LID - 10.1016/j.jviromet.2021.114074 [doi]
AB  - Recently, immunoblots (IBs) have tended to substitute Western blots (WBs) for HIV 
      infection diagnosis. Several studies have confirmed IBs' high sensitivity to 
      confirm HIV infection for every stage. Since the nature and pattern of the 
      antigens of IBs are different from those of WB, the abilities of IBs and WBs to 
      distinguish the stages of recent seroconversion and open-ended chronic infection 
      might differ. We aimed to evaluate the performance of two IBs (INNO-LIA™ HIVI/II, 
      Fujirebio, and Geenius™ HIV1/2 Confirmatory assay, Bio-Rad) to define the stage 
      of infection. We studied 53 patients from the French ANRS CO6 PRIMO cohort. IBs 
      have higher positive rates than WB. However, Geenius was less sensitive than WB 
      and INNO-LIA to detect antibodies to p31 (0% vs 22.6 % and 15.1 %, respectively), 
      so it could wrongly label late Fiebig stage and open-ended chronic infections as 
      recent infections (n = 5/53). For the first time, we provide evidence that 
      centralized WBs associated with an enzyme immunoassay for the identification of 
      recent HIV-1 infection support the establishment of a more accurate diagnosis of 
      primary HIV infection to improve the accuracy of enrollments in cohorts of recent 
      HIV infections useful for epidemiological studies, pathogenesis studies or 
      therapeutic trials.
CI  - Copyright © 2021 Elsevier B.V. All rights reserved.
FAU - Mariaggi, Alice-Andrée
AU  - Mariaggi AA
AD  - Université Paris Descartes, Sorbonne Paris Cité, Faculté de Médecine, Paris, 
      France; INSERM, U1016, CNRS, UMR8104, Institut Cochin, Paris, France; APHP, 
      Laboratoire de Virologie, CHU Cochin, Paris, France.
FAU - Gardiennet, Elise
AU  - Gardiennet E
AD  - Université Paris Descartes, Sorbonne Paris Cité, Faculté de Médecine, Paris, 
      France; INSERM, U1016, CNRS, UMR8104, Institut Cochin, Paris, France.
FAU - Stefic, Karl
AU  - Stefic K
AD  - CHU Bretonneau & Université François Rabelais, Centre National de Référence du 
      VIH-Laboratoire Associé, Inserm, U1259, Tours, France.
FAU - Essat, Asma
AU  - Essat A
AD  - INSERM CESP U1018, University Paris Saclay, Hôpital Bicêtre, Assistance 
      Publique-Hôpitaux de Paris (APHP), Le Kremlin-Bicêtre, France.
FAU - Cheret, Antoine
AU  - Cheret A
AD  - Université Paris Descartes, Sorbonne Paris Cité, Faculté de Médecine, Paris, 
      France; INSERM, U1016, CNRS, UMR8104, Institut Cochin, Paris, France; Service de 
      Médecine Interne et d'Immunologie Clinique, Hôpital Bicêtre, Assistance 
      Publique-Hôpitaux de Paris (APHP), Le Kremlin-Bicêtre, France.
FAU - Goujard, Cécile
AU  - Goujard C
AD  - INSERM CESP U1018, University Paris Saclay, Hôpital Bicêtre, Assistance 
      Publique-Hôpitaux de Paris (APHP), Le Kremlin-Bicêtre, France; Service de 
      Médecine Interne et d'Immunologie Clinique, Hôpital Bicêtre, Assistance 
      Publique-Hôpitaux de Paris (APHP), Le Kremlin-Bicêtre, France.
FAU - Meyer, Laurence
AU  - Meyer L
AD  - INSERM CESP U1018, University Paris Saclay, Hôpital Bicêtre, Assistance 
      Publique-Hôpitaux de Paris (APHP), Le Kremlin-Bicêtre, France.
FAU - Barin, Francis
AU  - Barin F
AD  - CHU Bretonneau & Université François Rabelais, Centre National de Référence du 
      VIH-Laboratoire Associé, Inserm, U1259, Tours, France.
FAU - Avettand-Fenoel, Véronique
AU  - Avettand-Fenoel V
AD  - Université Paris Descartes, Sorbonne Paris Cité, Faculté de Médecine, Paris, 
      France; INSERM, U1016, CNRS, UMR8104, Institut Cochin, Paris, France; APHP, 
      Laboratoire de Microbiologie Clinique, Hôpital Necker-Enfants Malades, Paris, 
      France. Electronic address: veronique.avettand@aphp.fr.
CN  - ANRS PRIMO cohort
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20210122
PL  - Netherlands
TA  - J Virol Methods
JT  - Journal of virological methods
JID - 8005839
RN  - 0 (HIV Antibodies)
SB  - IM
MH  - *Blotting, Western
MH  - HIV Antibodies
MH  - *HIV Infections/diagnosis
MH  - *HIV-1/immunology
MH  - HIV-2/immunology
MH  - Humans
MH  - Immunoassay
MH  - Sensitivity and Specificity
OTO - NOTNLM
OT  - Geenius
OT  - HIV diagnosis
OT  - HIV primary infection
OT  - INNO-LIA
OT  - Immunoblot
OT  - Western blot
EDAT- 2021/01/25 06:00
MHDA- 2021/10/28 06:00
CRDT- 2021/01/24 20:34
PHST- 2020/10/08 00:00 [received]
PHST- 2020/12/14 00:00 [revised]
PHST- 2021/01/10 00:00 [accepted]
PHST- 2021/01/25 06:00 [pubmed]
PHST- 2021/10/28 06:00 [medline]
PHST- 2021/01/24 20:34 [entrez]
AID - S0166-0934(21)00013-6 [pii]
AID - 10.1016/j.jviromet.2021.114074 [doi]
PST - ppublish
SO  - J Virol Methods. 2021 Apr;290:114074. doi: 10.1016/j.jviromet.2021.114074. Epub 
      2021 Jan 22.

PMID- 14761723
OWN - NLM
STAT- MEDLINE
DCOM- 20040317
LR  - 20191210
IS  - 0732-8893 (Print)
IS  - 0732-8893 (Linking)
VI  - 48
IP  - 1
DP  - 2004 Jan
TI  - The significance of combining World Health Organization and Center for Disease 
      Control criteria to resolve indeterminate human immunodeficiency virus type-1 
      Western blot results.
PG  - 59-61
AB  - A total of 466 repeatedly reactive HIV-1 blood samples evidenced by enzyme 
      immunoassay were analyzed by the Western blot method and interpreted according to 
      WHO and CDC criteria. Discordant and indeterminate samples were further analyzed 
      by PCR. When the Western blot result was classified as indeterminate, according 
      to both WHO and CDC criteria, the PCR test was always negative. These findings 
      suggest that samples with double-indeterminate status should be reported as 
      negative.
FAU - Tebourski, Fethi
AU  - Tebourski F
AD  - Laboratoire de Virologie (Laboratoire National de Référence pour l'infection à 
      VIH), Hôpital Charles Nicolle, Tunis, Tunisia. fateb@planet.tn
FAU - Slim, Amine
AU  - Slim A
FAU - Elgaaied, Amel
AU  - Elgaaied A
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - Diagn Microbiol Infect Dis
JT  - Diagnostic microbiology and infectious disease
JID - 8305899
SB  - IM
MH  - Blood/virology
MH  - Blotting, Western/*standards
MH  - Centers for Disease Control and Prevention, U.S.
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Female
MH  - *Guidelines as Topic
MH  - HIV Infections/diagnosis/virology
MH  - HIV-1/*isolation & purification
MH  - Humans
MH  - Male
MH  - Polymerase Chain Reaction
MH  - Sampling Studies
MH  - Sensitivity and Specificity
MH  - United States
MH  - World Health Organization
EDAT- 2004/02/06 05:00
MHDA- 2004/03/18 05:00
CRDT- 2004/02/06 05:00
PHST- 2003/05/23 00:00 [received]
PHST- 2003/07/26 00:00 [revised]
PHST- 2004/02/06 05:00 [pubmed]
PHST- 2004/03/18 05:00 [medline]
PHST- 2004/02/06 05:00 [entrez]
AID - S0732889303001883 [pii]
AID - 10.1016/j.diagmicrobio.2003.08.004 [doi]
PST - ppublish
SO  - Diagn Microbiol Infect Dis. 2004 Jan;48(1):59-61. doi: 
      10.1016/j.diagmicrobio.2003.08.004.

PMID- 17966582
OWN - NLM
STAT- MEDLINE
DCOM- 20080107
LR  - 20191210
IS  - 0375-0760 (Print)
IS  - 0375-0760 (Linking)
VI  - 57
IP  - 2
DP  - 2005 May-Aug
TI  - [Evaluation of the IgG anti-Toxoplasma response and its avidity by western-blot 
      in HIV-patients].
PG  - 125-32
AB  - The IgG anti-Toxoplasma western blot technique was used in 25 HIV-cases and 8 
      control sera from patients without HIV infection aimed at evaluating the humoral 
      response in these patients. They were divided into 3 groups: 14 HIV positive 
      cases with cerebral toxoplasmosis and IgG anti-Toxoplasma serological titers, 11 
      HIV positive cases without cerebral toxoplasmosis and with IgG anti-Toxoplasma 
      titers, and 8 HIV negative patients with IgG anti-Toxoplasma titers. It was found 
      that the higher the IgG anti-Toxoplasma serum titers are, the greater the number 
      of bands in the western-blot is. The intensity of the bands measured by 
      densitometry varied significantly for proteins of 66 and 31 kDa. According to the 
      results, these proteins are of interest to evaluate their role in the 
      reactivation of toxoplasmosis in HIV patients.
FAU - Cristina Sarmiento, María
AU  - Cristina Sarmiento M
AD  - Instituto de Salud en el Trópico, Facultad de Medicina-Universidad Nacional de 
      Colombia, Bogotá, Colombia.
FAU - Gómez Marín, Jorge Enrique
AU  - Gómez Marín JE
FAU - Castaño Osorio, Jhon Carlos
AU  - Castaño Osorio JC
LA  - spa
PT  - Comparative Study
PT  - Evaluation Study
PT  - Journal Article
TT  - Evaluación de la respuesta IgG anti-Toxoplasma y su avidez por western-blot en 
      pacientes infectados por VIH.
PL  - Cuba
TA  - Rev Cubana Med Trop
JT  - Revista cubana de medicina tropical
JID - 0074364
RN  - 0 (Antibodies, Protozoan)
RN  - 0 (Immunoglobulin G)
SB  - IM
MH  - AIDS-Related Opportunistic Infections/*diagnosis
MH  - Adult
MH  - Animals
MH  - Antibodies, Protozoan/*blood
MH  - *Blotting, Western
MH  - Data Interpretation, Statistical
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Female
MH  - Fluorescent Antibody Technique, Indirect
MH  - HIV Seropositivity/*complications
MH  - Humans
MH  - Immunoglobulin G/*blood
MH  - Male
MH  - Mice
MH  - Middle Aged
MH  - Pregnancy
MH  - Toxoplasma/*immunology
MH  - Toxoplasmosis, Cerebral/complications/*diagnosis/immunology
EDAT- 2007/10/31 09:00
MHDA- 2008/01/08 09:00
CRDT- 2007/10/31 09:00
PHST- 2007/10/31 09:00 [pubmed]
PHST- 2008/01/08 09:00 [medline]
PHST- 2007/10/31 09:00 [entrez]
PST - ppublish
SO  - Rev Cubana Med Trop. 2005 May-Aug;57(2):125-32.

PMID- 38907945
OWN - NLM
STAT- MEDLINE
DCOM- 20240622
LR  - 20241226
IS  - 1432-1831 (Electronic)
IS  - 0300-8584 (Linking)
VI  - 213
IP  - 1
DP  - 2024 Jun 22
TI  - Rapid tests should be used with caution for HIV-1 primary infection screening.
PG  - 10
LID - 10.1007/s00430-024-00792-1 [doi]
AB  - Rapid tests allow outpatient, low cost, reliable, screening for chronic HIV 
      infection. However, data regarding their sensitivity on primary infection remain 
      scarce. The objective of this study was to assess sensitivity of nine HIV rapid 
      tests for primary HIV-1 infection screening. Seventy-five serum samples from 
      patients during HIV-1 primary infection were included. Primary infection was 
      diagnosed by a positive 4th generation ELISA and HIV-1 RNA positivity confirmed 
      by Western blot patterns associated with HIV-1 primary infection. Early 
      seroconversion was defined as the absence of antibodies on HIV-1 Western blot 
      associated with HIV-1 RNA and p24-antigen positivity. An identical sensitivity 
      (95% CI) of 76.7% (65.2-84.2%) was observed for HIV 1/2 STAT-PAK(®) Assay 
      (STAT-PAK), INSTI™ HIV-1/HIV-2 antibody Test (INSTI), SURE CHECK(®) HIV 1/2 (SURE 
      CHECK) and MULTISURE HIV rapid test (MULTISURE) with visual reading. Sensitivity 
      was 74.7% (63.8-83.1%) for MULTISURE (automatic reading), 77.0% (66.3-85.1%) for 
      FIRST RESPONSE(®) Test VIH 1-2.O CARTE (FIRST RESPONSE), 83.8% (73.8-90.5%) for 
      VIKIA HIV1/2(®) (VIKIA), 88.0% (78.7-93.6%) for Genie™ Fast HIV 1/2 (Genie Fast), 
      88.6% (79.0-94.1%) for Hexagon HIV (Hexagon), and 92.8% (83.6-96.3%) for 
      Exacto(®) TEST HIV Pro (Exacto). However, rapid tests performed poorly for the 
      early seroconversion subgroup (n = 14), with sensitivities ranging from 7% 
      (1.3-31.5%) for STAT-PAK, INSTI, SURE CHECK, MULTISURE (automatic reading), to 
      29% (12-55%) for FIRST RESPONSE, 31% (13-58%) for VIKIA, 43% (21-67%) for Hexagon 
      and 57.1% (32.6-78.6%) for Exacto and Genie Fast. Overall, despite significant 
      discrepancies in sensitivity, HIV rapid tests should be used with caution in the 
      context of a suspected primary infection.
CI  - © 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, 
      part of Springer Nature.
FAU - Guiraud, Vincent
AU  - Guiraud V
AD  - Service de Virologie, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière-Charles 
      Foix, Paris, F- 75013, France.
FAU - Beaulieu, Quentin
AU  - Beaulieu Q
AD  - Service de Virologie, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière-Charles 
      Foix, Paris, F- 75013, France.
FAU - Fauchois, Antoine
AU  - Fauchois A
AD  - Service de Virologie, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière-Charles 
      Foix, Paris, F- 75013, France.
FAU - Jean-Charles, Pascale
AU  - Jean-Charles P
AD  - Service de Virologie, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière-Charles 
      Foix, Paris, F- 75013, France.
FAU - Costes, Marie-Capucine
AU  - Costes MC
AD  - Service de Virologie, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière-Charles 
      Foix, Paris, F- 75013, France.
FAU - Labousse, Bruno Le
AU  - Labousse BL
AD  - Service de Virologie, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière-Charles 
      Foix, Paris, F- 75013, France.
FAU - Gautheret-Dejean, Pr Agnès
AU  - Gautheret-Dejean PA
AD  - Service de Virologie, AP-HP, Hôpitaux Universitaires La Pitié Salpêtrière-Charles 
      Foix, Paris, F- 75013, France. agnes.gautheret@aphp.fr.
AD  - Université Paris cité, INSERM UMR-S 1139 Physiopathologie et pharmacotoxicologie 
      placentaire humaine : microbiote pré & post-natal, Paris, F-75006, France. 
      agnes.gautheret@aphp.fr.
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
DEP - 20240622
PL  - Germany
TA  - Med Microbiol Immunol
JT  - Medical microbiology and immunology
JID - 0314524
RN  - 0 (HIV Antibodies)
RN  - 0 (RNA, Viral)
SB  - IM
MH  - Humans
MH  - *HIV Infections/diagnosis
MH  - *Sensitivity and Specificity
MH  - *HIV-1/immunology/isolation & purification
MH  - Male
MH  - *Mass Screening/methods
MH  - Female
MH  - Adult
MH  - *HIV Antibodies/blood
MH  - Middle Aged
MH  - RNA, Viral/blood
MH  - Enzyme-Linked Immunosorbent Assay/methods
MH  - Young Adult
MH  - Blotting, Western/methods
MH  - Diagnostic Tests, Routine/methods
MH  - HIV Testing/methods
OTO - NOTNLM
OT  - HIV-1
OT  - Primary infection
OT  - Rapid test
OT  - Screening
OT  - Sensitivity
OT  - Seroconversion
EDAT- 2024/06/22 19:44
MHDA- 2024/06/22 19:45
CRDT- 2024/06/22 11:15
PHST- 2023/12/04 00:00 [received]
PHST- 2024/06/05 00:00 [accepted]
PHST- 2024/06/22 19:45 [medline]
PHST- 2024/06/22 19:44 [pubmed]
PHST- 2024/06/22 11:15 [entrez]
AID - 10.1007/s00430-024-00792-1 [pii]
AID - 10.1007/s00430-024-00792-1 [doi]
PST - epublish
SO  - Med Microbiol Immunol. 2024 Jun 22;213(1):10. doi: 10.1007/s00430-024-00792-1.

PMID- 31379346
OWN - NLM
STAT- MEDLINE
DCOM- 20200227
LR  - 20200227
IS  - 2261-2211 (Electronic)
IS  - 2261-3684 (Linking)
VI  - 29
IP  - 2
DP  - 2019 May 1
TI  - Prevalence of HIV infection among stroke patients in Douala.
PG  - 184-189
LID - 10.1684/mst.2019.0895 [doi]
AB  - To determine the prevalence of HIV infection among stroke patients admitted to 
      the Douala General Hospital (DGH) and to describe the clinical characteristics 
      and outcome of the stroke patients with HIV infection. This prospective cohort 
      study took place in 2010-2015 at the DGH. The study included patients older than 
      15 years with a CT-confirmed stroke. All patients underwent HIV tests with 
      Western-Blot confirmation. The functional prognosis of the patients was assessed 
      by the Rankin score at 6 months after stroke onset. The prevalence rate of HIV 
      among stroke patients was 6.6% (40/608). Of the 40 HIV-positive patients, 58% 
      were aware of their status at admission; 83% of these patients were receiving 
      antiretroviral therapy. Males were predominant (65%), and the mean age was 51.3 ± 
      10.4 years. Hypertension was the main cerebrovascular risk factor (65%). At 
      admission, 47.5% of HIV+ patients were febrile, and 7.5% presented with coma. 
      Ischemic stroke accounted for 60% of cases. The mean CD4 cell count was 351 ± 
      236/mm(3) with a median of 330/mm(3). The length of stay was 10 ± 8 days. At 6 
      months, the cumulative mortality of HIV+ patients was 37.5%, and 38.5% were 
      dependent (Rankin>2). HIV prevalence is high among stroke patients in our 
      setting. This suggests that an HIV test should be routinely proposed to stroke 
      patients.
FAU - Mapoure Njankouo, Y
AU  - Mapoure Njankouo Y
AD  - Faculté de médecine et des sciences pharmaceutiques, Université de Douala, 
      Douala, Cameroun.
FAU - Mondomobe Atchom, C
AU  - Mondomobe Atchom C
AD  - Faculté de médecine et des sciences pharmaceutiques, Université de Douala, 
      Douala, Cameroun.
FAU - Halle, M P
AU  - Halle MP
AD  - Faculté de médecine et des sciences pharmaceutiques, Université de Douala, 
      Douala, Cameroun.
FAU - Mbatchou Ngahane, B H
AU  - Mbatchou Ngahane BH
AD  - Faculté de médecine et des sciences pharmaceutiques, Université de Douala, 
      Douala, Cameroun.
FAU - Luma, N H
AU  - Luma NH
AD  - Faculté de médecine et des sciences pharmaceutiques, Université de Douala, 
      Douala, Cameroun.
LA  - eng
PT  - Journal Article
TT  - Prévalence de l’infection par le VIH chez les patients admis pour accident 
      vasculaire cérébral à Douala.
PL  - France
TA  - Med Sante Trop
JT  - Medecine et sante tropicales
JID - 101581406
SB  - IM
MH  - Adult
MH  - Cameroon/epidemiology
MH  - Female
MH  - HIV Infections/*complications/*epidemiology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Prevalence
MH  - Prospective Studies
MH  - Stroke/*complications
OTO - NOTNLM
OT  - Cameroon
OT  - HIV infection
OT  - prevalence
OT  - stroke
EDAT- 2019/08/06 06:00
MHDA- 2020/02/28 06:00
CRDT- 2019/08/06 06:00
PHST- 2019/08/06 06:00 [entrez]
PHST- 2019/08/06 06:00 [pubmed]
PHST- 2020/02/28 06:00 [medline]
AID - mst.2019.0895 [pii]
AID - 10.1684/mst.2019.0895 [doi]
PST - ppublish
SO  - Med Sante Trop. 2019 May 1;29(2):184-189. doi: 10.1684/mst.2019.0895.

PMID- 35867643
OWN - NLM
STAT- MEDLINE
DCOM- 20220726
LR  - 20220727
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 17
IP  - 7
DP  - 2022
TI  - Human T-Lymphotropic virus type 1 and human immunodeficiency virus co-infection 
      in rural Gabon.
PG  - e0271320
LID - 10.1371/journal.pone.0271320 [doi]
LID - e0271320
AB  - INTRODUCTION: Human T-cell lymphotrophic virus type-1 (HTLV-1) and human 
      immunodeficiency virus (HIV-1) co-infection occur in many populations. People 
      living with HIV-1 and infected with HTLV-1 seem more likely to progress rapidly 
      towards AIDS. Both HTLV-1 and HIV-1 are endemic in Gabon (Central Africa). We 
      investigated HTLV-1 and HIV-1 co-infection in the Haut-Ogooué province, and 
      assessed factors that may favor the rapid evolution and progression to AIDS in 
      co-infected patients. METHODS: Plasma samples from HTLV-1 patients were tested 
      using ELISA, and positive samples were then tested by western blot assay (WB). We 
      used the polymerase chain reaction to detect HTLV-1 Tax/Rex genes using DNA 
      extracted from the buffy coat of ELISA-positives samples. RESULTS: We recruited 
      299 individuals (mean age 46 years) including 90 (30%) men and 209 (70%) women, 
      all of whom are under treatment at the Ambulatory Treatment Centre of the 
      province. Of these, 45 were ELISA HTLV-1/2 seropositive. According to WB 
      criteria, 21 of 45 were confirmed positive: 20 were HTLV-1 (44%), 1 was HTLV-1/2 
      (2%), 2 were indeterminate (4%) and 22 were seronegative (49%). PCR results 
      showed that 23 individuals were positive for the Tax/Rex region. Considering both 
      serological and molecular assays, the prevalence of HTLV-1 infection was 
      estimated at 7.7%. Being a woman and increasing age were found to be independent 
      risk factors for co-infection. Mean CD4+ cell counts were higher in HTLV-1/HIV-1 
      co-infected (578.1 (± 340.8) cells/mm3) than in HIV-1 mono-infected (481.0 (± 
      299.0) cells/mm3) Individuals. Similarly, the mean HIV-1 viral load was Log 3.0 
      (± 1.6) copies/ml in mono-infected and Log 2.3 (± 0.7) copies/ml in coinfected 
      individuals. CONCLUSION: We described an overall high prevalence of HTLV-1/HIV-1 
      co-infection in Gabon. Our findings stress the need of strategies to prevent and 
      manage these co-infections.
FAU - Mouinga-Ondémé, Augustin
AU  - Mouinga-Ondémé A
AUID- ORCID: 0000-0002-3143-1060
AD  - Unité des Infections Rétrovirales et Pathologies Associées, Centre International 
      de Recherches Médicales de Franceville (CIRMF), Franceville, Gabon.
FAU - Boundenga, Larson
AU  - Boundenga L
AD  - Groupe Evolution et Transmission Inter-espèces des Pathogènes (GETIP), 
      Département de Parasitologie, Centre International de Recherches Médicales de 
      Franceville (CIRMF), Franceville, Gabon.
AD  - Department of Anthropology, Durham University, Durham, United Kingdom.
FAU - Koumba Koumba, Ingrid Précilya
AU  - Koumba Koumba IP
AD  - Unité des Infections Rétrovirales et Pathologies Associées, Centre International 
      de Recherches Médicales de Franceville (CIRMF), Franceville, Gabon.
AD  - Laboratoire de Biologie Moléculaire et Cellulaire (LABMC), Université des 
      Sciences et Techniques de Masuku (USTM), Franceville, Gabon.
FAU - Idam Mamimandjiami, Antony
AU  - Idam Mamimandjiami A
AD  - Unité des Infections Rétrovirales et Pathologies Associées, Centre International 
      de Recherches Médicales de Franceville (CIRMF), Franceville, Gabon.
FAU - Diané, Abdoulaye
AU  - Diané A
AD  - Unité des Infections Rétrovirales et Pathologies Associées, Centre International 
      de Recherches Médicales de Franceville (CIRMF), Franceville, Gabon.
FAU - Engone-Ondo, Jéordy Dimitri
AU  - Engone-Ondo JD
AD  - Unité des Infections Rétrovirales et Pathologies Associées, Centre International 
      de Recherches Médicales de Franceville (CIRMF), Franceville, Gabon.
FAU - Djuicy, Delia Doreen
AU  - Djuicy DD
AD  - Unité des Infections Rétrovirales et Pathologies Associées, Centre International 
      de Recherches Médicales de Franceville (CIRMF), Franceville, Gabon.
FAU - Sica, Jeanne
AU  - Sica J
AD  - Centre de Traitement Ambulatoire, Franceville, Gabon.
FAU - Mombo, Landry Erik
AU  - Mombo LE
AD  - Laboratoire de Biologie Moléculaire et Cellulaire (LABMC), Université des 
      Sciences et Techniques de Masuku (USTM), Franceville, Gabon.
FAU - Gessain, Antoine
AU  - Gessain A
AD  - Unité d'Epidémiologie et de Physiopathologie des Virus Oncogènes (EPVO), et CNRS 
      UMR3569, Institut Pasteur de Paris, Paris, France.
FAU - Aghokeng Fobang, Avelin
AU  - Aghokeng Fobang A
AD  - Unité Mixte de Recherche sur le VIH et les Maladies Infectieuses Associées, 
      Centre International de Recherches Médicales de Franceville (CIRMF), Franceville, 
      Gabon.
AD  - MIVEGEC, Université de Montpellier, CNRS, IRD - Montpellier, Montpellier, France.
LA  - eng
PT  - Journal Article
DEP - 20220722
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
SB  - IM
MH  - *Acquired Immunodeficiency Syndrome
MH  - Blotting, Western
MH  - *Coinfection/epidemiology
MH  - Female
MH  - Gabon/epidemiology
MH  - HIV
MH  - *HIV Infections/complications/epidemiology
MH  - *HTLV-I Infections/complications/epidemiology
MH  - *Human T-lymphotropic virus 1/genetics
MH  - Human T-lymphotropic virus 2/genetics
MH  - Humans
MH  - Male
MH  - Middle Aged
PMC - PMC9307203
COIS- The authors have declared that no competing interests exist.
EDAT- 2022/07/23 06:00
MHDA- 2022/07/27 06:00
PMCR- 2022/07/22
CRDT- 2022/07/22 13:33
PHST- 2021/06/16 00:00 [received]
PHST- 2022/06/28 00:00 [accepted]
PHST- 2022/07/22 13:33 [entrez]
PHST- 2022/07/23 06:00 [pubmed]
PHST- 2022/07/27 06:00 [medline]
PHST- 2022/07/22 00:00 [pmc-release]
AID - PONE-D-21-19756 [pii]
AID - 10.1371/journal.pone.0271320 [doi]
PST - epublish
SO  - PLoS One. 2022 Jul 22;17(7):e0271320. doi: 10.1371/journal.pone.0271320. 
      eCollection 2022.
